The study is a first-in-human (FIH), open-label, multi-center phase 1/2 study of TSN1611 in subjects with KRAS G12D mutant advanced solid tumors. This study will consist of a phase 1 dose escalation part and phase 2 dose expansion part.
The study is a first-in-human (FIH), open-label, multi-center phase 1/2 study of TSN1611 in subjects with KRAS G12D mutant advanced solid tumors. This study will consist of a phase 1 dose escalation part and phase 2 dose expansion part.
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
-
MD Anderson Cancer Center, Houston, Texas, United States, 77030
NEXT Oncology, San Antonio, Texas, United States, 78229
NEXT Virginia, Fairfax, Virginia, United States, 22031
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Tyligand Bioscience (Shanghai) Limited,
Cindy Li, STUDY_DIRECTOR, Tyligand Bioscience (Shanghai) Limited
2027-04-30